NCT03293498View on ClinicalTrials.gov

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

March 14, 2018

Study Completion Date

October 29, 2018

Conditions
Influenza
Interventions
BIOLOGICAL

NanoFlu

Vaccine

BIOLOGICAL

Fluzone HD - Day 0

Vaccine

BIOLOGICAL

Fluzone HD - Day 21

Vaccine

OTHER

Saline - Day 21

Placebo

Trial Locations (3)

27609

Research Site US108, Raleigh

27804

Research Site US106, Rocky Mount

28625

Research Site US132, Statesville

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT03293498 - Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) | Biotech Hunter | Biotech Hunter